181 Global skin disease morbidity and mortality: An update from the Global Burden of Disease Study 2013

Aksut, C. Karimkhani; Dellavalle, Robert P.; Naghavi, Mohsen

doi:10.1016/j.jid.2017.02.196

Cited by 163 publications

(246 citation statements)

References 9 publications

Supporting

Mentioning

232

Contrasting

Unclassified

Order By: Relevance

“…This allows for a dynamic data source for informing future policy and research. The 2013 and recently published 2015 iterations of GBD provide an overview of the burden of skin disease globally and allows for comparison of disease across time (6). …”

Section: Burden Of Skin Diseasementioning

confidence: 99%

“…15 skin disease categories were assessed: dermatitis, psoriasis, cellulitis, pyoderma, scabies, fungal skin diseases, viral skin diseases, acne vulgaris, alopecia areata, pruritus, urticarial, decubitus ulcer, malignant skin melanoma, and keratinocyte carcinoma (including basal and squamous cell carcinomas), and other skin conditions. Dermatitis (encompassing atopic, seborrheic, and contact types) resulted in the greatest burden of the skin conditions, costing 9.3 million DALYs (6). …”

Section: Burden Of Skin Diseasementioning

confidence: 99%

“…Persons of older age suffer disability burden from psoriasis, alopecia areata, urticaria, fungal skin diseases, and decubitus ulcers. These variations emphasize the need for region and population specific studies to truly understand the dermatologic needs of a community (6). …”

Section: Burden Of Skin Diseasementioning

confidence: 99%

See 2 more Smart Citations

Global Burden of Skin Disease: Inequities and Innovations

et al. 2017

View full text Add to dashboard Cite

Purpose of Review We review the current understanding of the burden of dermatological disease through the lens of the Global Burden of Disease project, evaluate the impact of skin disease on quality of life in a global context, explore socioeconomic implications, and finally summarize interventions towards improving quality of dermatologic care in resource-poor settings. Recent Findings The Global Burden of Disease project has shown that skin diseases continue to be the 4th leading cause of nonfatal disease burden world-wide. However, research efforts and funding do not match with the relative disability of skin diseases. International and national efforts, such as the WHO List of Essential Medicines, are critical towards reducing the socioeconomic burden of skin diseases and increasing access to care. Recent innovations such as teledermatology, point-of-care diagnostic tools, and task-shifting help to provide dermatological care to underserved regions in a cost-effective manner. Summary Skin diseases cause significant non-fatal disability worldwide, especially in resource-poor regions. Greater impetus to study the burden of skin disease in low resource settings and policy efforts towards delivering high quality care are essential in improving the burden of skin diseases.

show abstract

Section: Burden Of Skin Diseasementioning

confidence: 99%

Section: Burden Of Skin Diseasementioning

confidence: 99%

See 1 more Smart Citation

Global Burden of Skin Disease: Inequities and Innovations

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Over 5.4 million of these cancers are diagnosed in 3.3 million people in the United States annually, 2,3 and the global burden of disease from keratinocyte carcinomas is estimated at 12.9 disability-adjusted life years per 100,000 persons. 4 Generally keratinocyte carcinomas are not aggressive and do not metastasize or kill as often as melanoma, which is the third most common skin cancer. 5 However, SCC can metastasize and is estimated to kill between 3900 and 8800 people in the United States each year.…”

Section: Introduction Backgroundmentioning

confidence: 99%

“…Over 5.4 million of these lesions are diagnosed in 3.3 million people in the United States annually, 2, 3 and the global burden of disease from keratinocyte carcinomas is estimated at 12.9 disability-adjusted life years per 100,000 persons. 4 Generally keratinocyte carcinomas are not aggressive and do not metastasize or kill as often as melanoma, which is the third most common skin cancer.5 However, SCC can metastasize and is estimated to kill between 3900 and 8800 people in the United States each year.6 A more common problem is that BCC and SCC and their treatment may result in disfigurement or disability, which can adversely impact quality of life.3 The recent Surgeon General's call to action to prevent skin cancer at the population level emphasizes the public health importance of dealing with these cancers. …”

mentioning

confidence: 99%

Treatments for Basal Cell and Squamous Cell Carcinoma of the Skin

Drucker¹,

Adam²,

Langberg³

et al. 2017

View full text Add to dashboard Cite

Key MessagesPurpose of Review Assess comparative effectiveness and safety of treatments for basal cell carcinoma (BCC) and squamous cell carcinoma (SCC). Key Messages• Comparative evidence on treatment of BCC and SCC is limited. Many comparisons were evaluated in one or two randomized controlled trials only.• Surgery and radiotherapy have lower recurrence rates for BCC than interventions that destroy lesions with heat or cold, photodynamic therapy (PDT), or curettage.• There is moderate confidence that PDT for BCC is associated with better cosmetic outcomes than surgery.• Serious adverse events, events leading to treatment discontinuation, and treatment site infections were uncommon with all treatments for BCC.• Recurrence rates for SCC in situ were lower with PDT and cryotherapy than with drugs.Evidence was insufficient to draw conclusions for other treatments.ii This report is based on research conducted by the Brown Evidence-based Practice Center (EPC) under contract to the Agency for Healthcare Research and Quality (AHRQ), Rockville, MD (Contract No. 290-2015-00002-I). The findings and conclusions in this document are those of the authors, who are responsible for its contents; the findings and conclusions do not necessarily represent the views of AHRQ. Therefore, no statement in this report should be construed as an official position of AHRQ or of the U.S. Department of Health and Human Services.None of the investigators have any affiliations or financial involvement that conflicts with the material presented in this report.The information in this report is intended to help health care decisionmakers-patients and clinicians, health system leaders, and policymakers, among others-make well-informed decisions and thereby improve the quality of health care services. This report is not intended to be a substitute for the application of clinical judgment. Anyone who makes decisions concerning the provision of clinical care should consider this report in the same way as any medical reference and in conjunction with all other pertinent information, i.e., in the context of available resources and circumstances presented by individual patients.This report is made available to the public under the terms of a licensing agreement between the author and the Agency for Healthcare Research and Quality. This report may be used and reprinted without permission except those copyrighted materials that are clearly noted in the report. Further reproduction of those copyrighted materials is prohibited without the express permission of copyright holders.AHRQ or U.S. Department of Health and Human Services endorsement of any derivative products that may be developed from this report, such as clinical practice guidelines, other quality enhancement tools, or reimbursement or coverage policies, may not be stated or implied. This report may periodically be assessed for the currency of conclusions. If an assessment is done, the resulting surveillance report describing the methodology and findings will be found on the Effective Health Ca...

show abstract

Topographic Phenotypes of Alopecia Areata and Development of a Prognostic Prediction Model and Grading System

et al. 2019

View full text Add to dashboard Cite

IMPORTANCE Diverse assessment tools and classification have been used for alopecia areata; however, their prognostic values are limited. OBJECTIVE To identify the topographic phenotypes of alopecia areata using cluster analysis and to establish a prediction model and grading system for stratifying prognoses. DESIGN, SETTING, AND PARTICIPANTS A retrospective cohort study of 321 patients with alopecia areata who visited a single tertiary referral center between October 2012 and February 2017 and underwent 4-view photographic assessment. EXPOSURES Clinical photographs were reviewed to evaluate hair loss using the Severity of Alopecia Tool 2. Topographic phenotypes of alopecia areata were identified using hierarchical clustering with Ward's method. Differences in clinical characteristics and prognosis were compared across the clusters. The model was evaluated for its performance, accuracy, and interobserver reliability by comparison to conventional methods. MAIN OUTCOMES AND MEASURES Topographic phenotypes of alopecia areata and their major (60%-89%) and complete regrowth probabilities (90%-100%) within 12 months. RESULTS A total of 321 patients were clustered into 5 subgroups. Grade 1 (n = 200; major regrowth, 93.4%; complete regrowth, 65.2%) indicated limited hair loss, whereas grades 2A (n = 66; major regrowth, 87.8%; complete regrowth, 64.2%) and 2B (n = 20; major regrowth, 73.3%; complete regrowth, 45.5%) exhibited greater hair loss than grade 1. The temporal area was predominantly involved in grade 2B, but not in grade 2A, despite being comparable in total extent of hair loss. Grade 3 (n = 20; major regrowth, 45.5%; complete regrowth, 25.5%) included diffuse or extensive alopecia areata, and grade 4 (n = 15; major regrowth, 28.2%; complete regrowth, 16.7%) corresponded to alopecia (sub)totalis. No significant differences in prognosis (hazard ratio [HR] for major regrowth, 0.79; 95% CI, 0.56-1.12) were found between grades 2A and 1, whereas grades 2B (HR, 0.41; 95% CI, 0.21-0.81), 3 (HR, 0.24; 95% CI, 0.12-0.50), and 4 (HR, 0.16; 95% CI, 0.06-0.39) had significantly poorer response. Among multiple models, the cluster solution had the greatest prognostic performance and accuracy. The tree model of the cluster solution was converted into the Topography-based Alopecia Areata Severity Tool (TOAST), which revealed an excellent interobserver reliability among 4 dermatologists (median quadratic-weighted κ, 0.89). CONCLUSIONS AND RELEVANCE Temporal area involvement should be independently measured for better prognostic stratification. The TOAST is an effective tool for describing the topographical characteristics and prognosis of hair loss and may enable clinicians to establish better treatment plans.

show abstract

181 Global skin disease morbidity and mortality: An update from the Global Burden of Disease Study 2013

Cited by 163 publications

References 9 publications

Global Burden of Skin Disease: Inequities and Innovations

Global Burden of Skin Disease: Inequities and Innovations

Treatments for Basal Cell and Squamous Cell Carcinoma of the Skin

Topographic Phenotypes of Alopecia Areata and Development of a Prognostic Prediction Model and Grading System

Contact Info

Product

Resources

About